(Q33413862)

English

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Pancras C.W. Hogendoorn

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Angelo Paolo Dei Tos

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Hans J. Gelderblom

3

object named as

Hans Gelderblom

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2

object named as

Jaap Verweij

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Peter Hohenberger

10

object named as

Peter Hohenberger

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1

object named as

Ian Judson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Jörg T Hartmann

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

J Martijn Kerst

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Josef Sufliarsky

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jeremy Whelan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Anders Krarup-Hansen

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Thierry Alcindor

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sandrine Marreaud

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Saskia Litière

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Catherine Hermans

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Cyril Fisher

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Winette T A van der Graaf

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Patrick Schöffski

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

5 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

415-423

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970063-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70063-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

release_4skde6urzfcqvealxqjvbcumoe

1 reference

https://api.fatcat.wiki/v0/release/4skde6urzfcqvealxqjvbcumoe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618336%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33413862&oldid=1952585140"